MacroGenics, Inc.
MGNX Real Time Price USDRecent trades of MGNX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MGNX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
MGNX Revenue by Segment or Geography
New patents grants
-
Patent Title: Her2/neu-specific antibodies and methods of using same Jul. 02, 2024
-
Patent Title: Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof Mar. 26, 2024
-
Patent Title: Lag-3-binding molecules and methods of use thereof Jan. 02, 2024
-
Patent Title: Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4 Dec. 12, 2023
-
Patent Title: Multi-chain polypeptide-containing tri-specific binding molecules Nov. 21, 2023
-
Patent Title: Bispecific cd16-binding molecules and their use in the treatment of disease Oct. 24, 2023
-
Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fegammarinhibiting Oct. 17, 2023
-
Patent Title: Tri-specific binding molecules that specifically bind to multiple cancer antigens Jul. 11, 2023
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof May. 02, 2023
-
Patent Title: Pd-1-binding molecules and methods of use thereof Apr. 11, 2023
-
Patent Title: B7-h3 directed antibody drug conjugates Feb. 28, 2023
-
Patent Title: Pharmaceutical compositions of a her2/neu antibody and use of the same Oct. 04, 2022
-
Patent Title: Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof Oct. 04, 2022
-
Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Aug. 23, 2022
-
Patent Title: Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof Jul. 12, 2022
-
Patent Title: Covalent diabodies and uses thereof Feb. 22, 2022
-
Patent Title: Covalent diabodies and uses thereof Feb. 22, 2022
-
Patent Title: Adam9-binding molecules, and methods of use thereof Feb. 08, 2022
-
Patent Title: Combination therapy for the treatment of cancer Nov. 16, 2021
-
Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Sep. 07, 2021
-
Patent Title: Fcγriib-specific antibodies and methods of use thereof Aug. 24, 2021
-
Patent Title: Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof Aug. 24, 2021
-
Patent Title: Combination therapy for the treatment of cancer Aug. 03, 2021
-
Patent Title: Lag-3-binding molecules and methods of use thereof Jul. 27, 2021
-
Patent Title: Her2/neu-specific antibodies and methods of using same Jun. 08, 2021
-
Patent Title: B7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof Mar. 30, 2021
-
Patent Title: Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof Mar. 23, 2021
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof Dec. 08, 2020
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof Sep. 29, 2020
-
Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Aug. 04, 2020
-
Patent Title: Antibodies reactive with b7-h3 and users thereof Aug. 04, 2020
-
Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcγr Jul. 14, 2020
-
Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jun. 16, 2020
-
Patent Title: Multi-chain polypeptide-containing tri-specific binding molecules May. 12, 2020
-
Patent Title: Pd-1-binding molecules and methods of use thereof Mar. 03, 2020
-
Patent Title: Multivalent molecules comprising dr5-binding domains Dec. 10, 2019
-
Patent Title: Bcr-complex-specific antibodies and methods of using same Nov. 19, 2019
-
Patent Title: Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof Jul. 09, 2019
-
Patent Title: Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof Dec. 25, 2018
-
Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Dec. 11, 2018
-
Patent Title: Her2/neu-specific antibodies and methods of using same Nov. 20, 2018
-
Patent Title: Fcγriib-specific antibodies and methods of use thereof Oct. 16, 2018
-
Patent Title: Methods for the treatment of vascularizing cancers Oct. 16, 2018
-
Patent Title: Covalent diabodies and uses thereof Oct. 09, 2018
-
Patent Title: Covalent diabodies and uses thereof Oct. 09, 2018
-
Patent Title: Covalent diabodies and uses thereof May. 08, 2018
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof Apr. 03, 2018
-
Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Mar. 06, 2018
-
Patent Title: Antibodies reactive with b7-h3 and uses thereof Feb. 20, 2018
-
Patent Title: Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin Feb. 13, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MGNX
Recent picks made for MGNX stock on CNBC
ETFs with the largest estimated holdings in MGNX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MGNX stock a Buy, Sell, or Hold?
- What is the price target for $MGNX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MGNX stock?
- Who owns the most shares of $MGNX stock?
- What funds own $MGNX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MGNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.